Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.10.2018 | Case report

Ipilimumab/nivolumab

Thrombocytopenia, neutropenia and autoimmune hepatitis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Philipp M, et al. Pseudoprogression with subsequent complete response and severe thrombocytopenia to checkpoint inhibitor immunotherapy in a patient with advanced mucosal melanoma of the sinonasal cavity. Anti-Cancer Drugs 29: 914-918, No. 9, Oct 2018. Available from: URL: http://doi.org/10.1097/CAD.0000000000000664 - Austria Philipp M, et al. Pseudoprogression with subsequent complete response and severe thrombocytopenia to checkpoint inhibitor immunotherapy in a patient with advanced mucosal melanoma of the sinonasal cavity. Anti-Cancer Drugs 29: 914-918, No. 9, Oct 2018. Available from: URL: http://​doi.​org/​10.​1097/​CAD.​0000000000000664​ - Austria
Metadaten
Titel
Ipilimumab/nivolumab
Thrombocytopenia, neutropenia and autoimmune hepatitis: case report
Publikationsdatum
01.10.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-53525-4

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Acetylcysteine

Case report

Crizotinib

Case report

Bupivacaine

Case report

Mefenamic-acid

Case report

Acenocoumarol